You are here

semaglutide

Novo, Viking heat up MASH space with promising data at AASLD24

BioSpace

Wed, 11/20/24 - 11:40 am

Viking Therapeutics

Compounded Ozempic tied to deaths, hospitalizations: Novo Nordisk CEO

Beckers Hospital Review

Thu, 11/7/24 - 11:14 am

compounded drugs

Novo, with new results, to seek approval for obesity drug in MASH

BioPharma Dive

Fri, 11/1/24 - 11:25 am

Novo builds heart failure case for semaglutide

BioPharma Dive

Fri, 08/30/24 - 11:31 am

cardiovascular disease

Medicare Coverage of Novo’s Semaglutide for CVD Could Cost $145B Annually: Study

BioSpace

Tue, 08/27/24 - 11:32 am

cardiovascular disease

Novo Nordisk plots 2024 FDA filing for once-weekly insulin and semaglutide combo

Fierce Pharma

Mon, 08/12/24 - 06:01 pm

Weight loss drug could reduce heart attack risk by 20%, study finds

The Guardian, UK

Tue, 05/14/24 - 11:51 am

Novo Ends Semaglutide Kidney Study Early Due to Strong Efficacy Signals

BioSpace

Wed, 10/11/23 - 10:15 am

clinical trials

chronic kidney disease

Inside the FDA's Form 483 findings at Novo Nordisk's North Carolina semaglutide plant

Fierce Pharma

Tue, 09/19/23 - 10:19 pm

drug manufacturing

After treatment with semaglutide, people with newly diagnosed type 1 diabetes needed little or no insulin

Medical News Today

Sun, 09/10/23 - 08:03 pm

type 1 diabetes

Obesity: Six trials to watch over the next 12 months

Clinical Trials Arena

Fri, 06/30/23 - 11:45 am

clinical trials

Innovent Biologics

Novo Nordisk says EMA raised safety signal on drugs including semaglutide

Yahoo/Reuters

Thu, 06/22/23 - 10:21 am

Eli Lilly's Mounjaro is primed to surpass Novo Nordisk's popular diabetes and obesity duo: report

Fierce Pharma

Mon, 06/19/23 - 10:29 am

Novo Nordisk’s trial of oral semaglutide meets primary endpoint

Clinical Trials Arena

Tue, 05/23/23 - 09:56 am

oral semaglutide

clinical trials

Novo Nordisk's GLP-1 for Type II diabetes approved for first-line treatment

Endpoints

Fri, 01/13/23 - 11:10 am

type 2 diabetes

A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity

Fierce Pharma

Mon, 08/29/22 - 10:40 am

Alzheimer's disease

Novo Nordisk successfully completes phase 2 trial with CagriSema in people with type 2 diabetes

Yahoo Finance

Mon, 08/22/22 - 10:00 am

clinical trials

type 2 diabetes

After phase 2 flop, Novo Nordisk says its NASH work is 'still very much on track'

Fierce Pharma

Wed, 06/29/22 - 05:43 pm

Novo Nordisk, armed with Wegovy green light, preps aggressive push to build obesity market

Fierce Pharma

Tue, 06/8/21 - 12:21 pm

Novo Nordisk's semaglutide set to tackle obesity with hotly-anticipated FDA green light

Fierce Pharma

Sat, 06/5/21 - 02:26 pm

Pages